These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22705888)

  • 21. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
    Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
    Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets.
    Duvernay MT; Temple KJ; Maeng JG; Blobaum AL; Stauffer SR; Lindsley CW; Hamm HE
    Mol Pharmacol; 2017 Jan; 91(1):39-47. PubMed ID: 27784794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
    Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
    Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.
    Covic L; Gresser AL; Kuliopulos A
    Biochemistry; 2000 May; 39(18):5458-67. PubMed ID: 10820018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
    Bilodeau ML; Hamm HE
    J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel mechanism regulating human platelet activation by MMP-2-mediated PAR1 biased signaling.
    Sebastiano M; Momi S; Falcinelli E; Bury L; Hoylaerts MF; Gresele P
    Blood; 2017 Feb; 129(7):883-895. PubMed ID: 28034890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
    Wu CC; Teng CM
    Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 12(S)-HETrE, a 12-Lipoxygenase Oxylipin of Dihomo-γ-Linolenic Acid, Inhibits Thrombosis via Gαs Signaling in Platelets.
    Yeung J; Tourdot BE; Adili R; Green AR; Freedman CJ; Fernandez-Perez P; Yu J; Holman TR; Holinstat M
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2068-77. PubMed ID: 27470510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
    Lee H; Sturgeon SA; Jackson SP; Hamilton JR
    Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach.
    Covic L; Kuliopulos A
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30065181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Kv1.3 Channels in Platelet Functions and Thrombus Formation.
    Fan C; Yang X; Wang WW; Wang J; Li W; Guo M; Huang S; Wang Z; Liu K
    Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):2360-2375. PubMed ID: 32787516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New thoughts on strategies for modulating platelet function through the inhibition of surface receptors.
    Nurden AT
    Haemostasis; 1996 Oct; 26 Suppl 4():78-88. PubMed ID: 8979114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
    Rana R; Huang T; Koukos G; Fletcher EK; Turner SE; Shearer A; Gurbel PA; Rade JJ; Kimmelstiel CD; Bliden KP; Covic L; Kuliopulos A
    Arterioscler Thromb Vasc Biol; 2018 Jun; 38(6):1368-1380. PubMed ID: 29622563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis.
    Voss B; McLaughlin JN; Holinstat M; Zent R; Hamm HE
    Mol Pharmacol; 2007 May; 71(5):1399-406. PubMed ID: 17303701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor-mediated inhibitory mechanisms and the regulation of platelet function.
    Cheng Z; Liu J
    Sci China Life Sci; 2015 Dec; 58(12):1299-301. PubMed ID: 26588910
    [No Abstract]   [Full Text] [Related]  

  • 36. The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy.
    Warner TD; Armstrong PC; Chan MV; Knowles RB
    Expert Rev Hematol; 2016 Mar; 9(3):223-5. PubMed ID: 26822235
    [No Abstract]   [Full Text] [Related]  

  • 37. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vorapaxar for the reduction of atherothrombotic events.
    Diaz-Ricart M; Escolar G
    Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolution of platelet-directed pharmacotherapy.
    Becker RC; Smyth S
    J Thromb Haemost; 2009 Jul; 7 Suppl 1():266-71. PubMed ID: 19630814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Esculetin, a Coumarin Derivative, Prevents Thrombosis: Inhibitory Signaling on PLCγ2-PKC-AKT Activation in Human Platelets.
    Hsia CW; Lin KC; Lee TY; Hsia CH; Chou DS; Jayakumar T; Velusamy M; Chang CC; Sheu JR
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.